Our ID NOW test for COVID-19 is the fastest molecular point-of-care rapid test available today and has been delivering reliable results when and where they’re needed. Because of its ease of use, portability and rapid results, ID NOW is providing frontline healthcare workers with a tool that they hoped for when the COVID-19 pandemic first took hold across the world.
An interim analysis of a study examining ID NOW’s performance in urgent care clinics shows ≥94.7% in positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) when compared to two different lab-based PCR reference tests. Those early results, part of two ongoing multi-site clinical studies, are happening in the real-world situations found in urgent care clinics and strongly suggest ID NOW — which delivers results in minutes, not days — performs best when people are tested earlier after they first experience symptoms.
The world needs a variety of tests in labs and at the point of care if we are to help reduce the spread and risk of infection by diagnosing COVID-19. ID NOW is an important tool in that equation. Helping people is the goal, which is why we’re developing and continually optimizing as many tests as we can across all of our diagnostics platforms.
ID NOW has quickly become an important tool in the fight against COVID-19 outside of traditional hospital settings.
- Some hospitals use it to test patients before surgery.
- People who need chemotherapy and are behind in their treatments are now able to be tested quickly so they can get back to the hospital to continue on their journey to recovery.
- Urgent care centers and pharmacy clinics are using the test in point-of-care sites throughout the country.